These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20361277)

  • 1. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
    Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
    Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
    Apollonsky N; Lipton JM
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
    Robak T; Błasińska-Morawiec M; Krykowski E; Hellmann A; Lewandowski K; Dmoszyńska A; Adamczyk-Cioch M; Kazimierczak M; Trepińska E; Dwilewicz-Trojaczek M; Kuratowska Z; Skotnicki AB; Nowak WS; Zdziarska B; Urasiński I
    Eur J Haematol; 1997 Oct; 59(4):216-20. PubMed ID: 9338619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients.
    Stine KC; Saylors RL; Williams LL; Becton DL
    Med Pediatr Oncol; 1997 Oct; 29(4):288-92. PubMed ID: 9251735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research].
    Sperb RA; von Rohr A; Ratschiller D; Bacchi M; Tichelli A; Hess U; Cerny T; Tobler A; Betticher DC
    Schweiz Med Wochenschr; 1998 Oct; 128(42):1593-7. PubMed ID: 9824888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
    Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
    Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
    Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
    Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with 2-chlorodeoxyadenosine of refractory pediatric Langerhans cell histiocytosis with initial involvement of the gastrointestinal tract.
    Mayumi A; Imamura T; Sakamoto K; Ota T; Osone S; Usami I; Hosoi H
    Int J Hematol; 2019 Dec; 110(6):756-762. PubMed ID: 31350665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27454. PubMed ID: 30207064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
    Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
    J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.